0000000001322809

AUTHOR

Edoardo Spina

showing 6 related works from this author

A systematic review and combined analysis of therapeutic drug monitoring studies for longacting risperidone

2017

Introduction: This systematic review of therapeutic drug monitoring (TDM) identifies three long-acting injectable (LAI) risperidone formulations. Areas covered: Limited data is available on two formulations (RBP-7000 and in Situ Microparticle), but 20 TDM articles on the microsphere formulation were found. Risperidone TDM includes the serum concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, used for calculating: 1) the risperidone/9-hydroxyrisperidone (R/9-OH-R) ratio (a measure of CYP2D6; values >1 are indicative of a CYP2D6 poor metabolizer) and 2) the total risperidone concentration-to-dose (C/D) ratio (a measure of risperidone clearance with a normal value…

CYP2D6Therapeutic drug monitoring studiesAdministration OralPharmacologyMicrosphereInjections03 medical and health sciences0302 clinical medicineLong acting risperidonePaliperidone PalmitatemedicineAnimalsHumansPharmacology (medical)General Pharmacology Toxicology and Pharmaceutics610 Medicine & healthActive metabolitePaliperidone PalmitateRisperidonemedicine.diagnostic_testbusiness.industryGeneral MedicineRisperidoneMicrospheres030227 psychiatryAntipsychotic agents/administration & dosage; delayed-action preparations; drug monitoring; injections; risperidone/administration & dosage; risperidone/blood; risperidone/metabolism; risperidone/pharmacokinetics; risperidone/pharmacology; risperidone/therapeutic use; schizophrenia/drug therapyTherapeutic drug monitoringDelayed-Action PreparationsDrug Monitoringbusiness030217 neurology & neurosurgerymedicine.drugAntipsychotic Agents
researchProduct

Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidep…

2021

Contains fulltext : 238693.pdf (Publisher’s version ) (Open Access) Objectives: More than 40 drugs are available to treat affective disorders. Individual selection of the optimal drug and dose is required to attain the highest possible efficacy and acceptable tolerability for every patient.Methods: This review, which includes more than 500 articles selected by 30 experts, combines relevant knowledge on studies investigating the pharmacokinetics, pharmacodynamics and pharmacogenetics of 33 antidepressant drugs and of 4 drugs approved for augmentation in cases of insufficient response to antidepressant monotherapy. Such studies typically measure drug concentrations in blood (i.e. therapeutic …

Drugmedicine.medical_specialtyprecision medicinetherapeutic drug monitoringmedia_common.quotation_subjectStress-related disorders Donders Center for Medical Neuroscience [Radboudumc 13]brain imagingNeuroimagingPsykiatri03 medical and health sciences0302 clinical medicinePharmacotherapyNeuroimagingmedicineHumansIntensive care medicineBiological Psychiatrypharmacogeneticsmedia_commonPsychiatrymedicine.diagnostic_testbusiness.industryAntidepressantsPrecision medicineAntidepressive Agents030227 psychiatryPsychiatry and Mental healthTherapeutic drug monitoringPharmacogeneticsAntidepressants; brain imaging; pharmacogenetics; precision medicine; therapeutic drug monitoring; Antidepressive Agents; Drug Monitoring; Humans; Neuroimaging; Pharmacogenetics; PsychiatryAntidepressants; brain imaging; precision medicine; pharmacogenetics; therapeutic drug monitoringDrug MonitoringbusinessPharmacogeneticsWorld Journal of Biological Psychiatry
researchProduct

High mobility group box 1 and markers of oxidative stress in human cord blood.

2019

Background Parturition induces considerable oxidative stress and many inflammatory mediators, such as high mobility group box 1 (HMGB1), are involved from the beginning of the pregnancy to birth. The aim of the present study was to evaluate serum cord blood concentration of diacron-reactive oxygen metabolites (d-ROM), biological antioxidant potential (BAP), and HMGB1 to investigate the perinatal oxidative status of neonates and correlation with mode of delivery, as well as the influence of labor. Methods The subjects consisted of 214 neonates delivered at University Hospital "G. Martino", Messina, in a 6 months period. Venous blood samples were collected from the umbilical cord after cord s…

CordPhysiology030204 cardiovascular system & hematologyHMGB1medicine.disease_causeUmbilical cordUmbilical veinAntioxidants03 medical and health sciences0302 clinical medicinePregnancy030225 pediatricsMedicineHumansHMGB1 ProteinPregnancyLabor Obstetricbiologybusiness.industryInfant NewbornCord blood high mobility group box 1 newborn oxidative stress pregnancy.cord blood high mobility group box 1 newborn oxidative stress pregnancyVenous bloodmedicine.diseaseDelivery ObstetricFetal BloodOxidative Stressmedicine.anatomical_structureItalyCord bloodPediatrics Perinatology and Child Healthbiology.proteinFemalebusinessReactive Oxygen SpeciesOxidative stressBiomarkers
researchProduct

A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adul…

2019

Introduction: This article comprehensively reviews the clinical utility of the serum clozapine/norclozapine (CLO/NCLO) ratio. Areas covered: Fifty-four published studies used this ratio (21 from a PubMed search from onset to 10/21/18 and 33 identified by the authors). To estimate a combined mean of the CLO/NCLO ratio in published studies, a PubMed search on 10/21/18 identified 422 articles leading to 19 included. The systematic review focused on 1) the combined analysis, 2) CYP1A2 activity, 3) clinical response, 4) cognition, and 5) renal function. Expert opinion: Our combined analysis provided a weighted mean CLO/NCLO ratio of 1.73 in 2,317 adult patients from 19 studies, but the range in …

OncologyAdultmedicine.medical_specialtyClozapine+NorclozapineRenal function030226 pharmacology & pharmacylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicineGemfibrozilAnimalsHumansPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsClozapineClozapineRandomized Controlled Trials as TopicAdult patientsmedicine.diagnostic_testbusiness.industryGeneral MedicineTherapeutic drug monitoring030220 oncology & carcinogenesisDrug MonitoringbusinessRenal transportersmedicine.drugAntipsychotic AgentsExpert review of clinical pharmacology
researchProduct

Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics.

2016

Second-generation antipsychotics (SGAs) are frequently co-prescribed with drug metabolic inducers and inhibitors. SGA pharmacokinetic drug-drug interactions (DDIs) with inducers and inhibitors have not received enough attention in the literature but can be studied in by using therapeutic drug monitoring (TDM).The limited information available on oral SGA pharmacokinetic DDIs is reviewed. A systematic literature search on the available oral SGA TDM studies is completed. By integrating TDM studies with the information on in vitro metabolism studies, case report/series and prospective studies, a table is provided to manage average SGA patients taking inducers or inhibitors by using TDM and/or …

DrugDrug-Related Side Effects and Adverse Reactionsmedia_common.quotation_subjecttherapeutic drug monitoringAdministration OralPharmacologyToxicology030226 pharmacology & pharmacyDrug interactions03 medical and health sciences0302 clinical medicinePharmacokineticsinhibitorsMedicineHumansProspective cohort studyClozapinemedia_commonLurasidoneinducersPharmacologyRisperidonemedicine.diagnostic_testDose-Response Relationship Drugbusiness.industrysecond-generation antipsychoticsGeneral MedicineDrug interactions; inducers; inhibitors; pharmacokinetics; second-generation antipsychotics; therapeutic drug monitoring030227 psychiatryTherapeutic drug monitoringQuetiapineAntidepressive Agents Second-GenerationDrug Monitoringbusinesspharmacokineticsmedicine.drugAntipsychotic Agents
researchProduct

A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone

2017

Introduction: This systematic review of therapeutic drug monitoring (TDM) identifies three long-acting injectable (LAI) risperidone formulations. Areas covered: Limited data is available on two formulations (RBP-7000 and in Situ Microparticle), but 20 TDM articles on the microsphere formulation were found. Risperidone TDM includes the serum concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, used for calculating: 1) the risperidone/9-hydroxyrisperidone (R/9-OH-R) ratio (a measure of CYP2D6; values >1 are indicative of a CYP2D6 poor metabolizer) and 2) the total risperidone concentration-to-dose (C/D) ratio (a measure of risperidone clearance with a normal value…

researchProduct